Pentagamavunon-0 (PGV-0) Enhance Cytotoxic Effect of Doxorubicin through Increasing of Apoptosis, Senescence and ROS Level on Triple Negative Breast Cancer 4T1 by Hadi, Ismanurrahman et al.
 7
Indonesian Journal of Cancer Chemoprevention, February 2020
ISSN: 2088–0197
e-ISSN: 2355-8989
Pentagamavunon-0 (PGV-0) Enhance Cytotoxic Effect of 
Doxorubicin Through Increasing of Apoptosis, Senescence and 
ROS Level on Triple Negative Breast Cancer 4T1
Ismanurrahman Hadi1,2, Riris Istighfari Jenie2,3, Edy Meiyanto2,3*
1Magister Program of Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
2Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
3Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
Abstract
  
 Triple negative breast cancer (TNBC), one of the sub type of breast cancers was widely 
known with high tumorigenic and poor prognosis than others. The development of combination 
agent (co-chemotherapy) with doxorubicin for chemotherapy of TNBC were carried out to 
decrease doxorubicin side effect and resistance in cancer. This present study aims to explore 
the co-chemotherapeutic properties of Pentagamavunon-0 (PGV-0) and investigate induction 
of doxorubicin on apoptosis, senescence and Reactive Oxygen Species (ROS) against TNBC. 
4T1 Cell line was used as a TNBC in vitro model. Cytotoxic measurement was performed 
using 3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazolium bromide (MTT) assay resulting in IC50 
values of 52 μM. Meanwhile, the combination of doxorubicin and PGV-0 showed synergistic 
effect which decreased cell viability of 4T1 better than single treatment of doxorubicin. 
Apoptosis analysis was performed using annexin V/PI assay indicated that the combination 
treatment of PGV-0 and doxorubicin increased apoptosis evidence. Senescence detection was 
carried out using senescence-associated-β galactosidase (SA-β-GAL) assay. The results showed 
that a single treatment of PGV-0 induced cellular senescence and increased senescence cells 
in combination treatment. Moreover, 2’,7’-dichlorofluorescein diacetate (DCFDA) staining 
showed that PGV-0 increased ROS level at single treatment, whereas combination treatment 
increased ROS intracellular compared to the positive control of doxorubicin. Based on these 
results, PGV-0 has potential as a co-chemotherapeutic candidate on TNBC.
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INTRODUCTION
 Triple negative breast cancer (TNBC), 
one of the highly tumorigenic of breast cancers 
is known as difficult to treat due to the lacking 
of estrogen receptor, progesterone receptor and 
human epidermal receptor-2 (HER-2) (O’Reilly, et 
al., 2015). TNBC chemotherapy uses doxorubicin 
with a broad spectrum of action. Nevertheless, 
long term usage of doxorubicin can cause side 
effects such as cardiotoxicity and resistance of 
doxorubicin in cancer (Hanna, et al., 2014). The 
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recent development of TNBC chemotherapy 
directed to find a potential combination agent (co-
chemotherapy) that can increase the effectiveness 
of doxorubicin. In this regard, doxorubicin is 
hopefully to forms a synergistic effect with co-
chemotherapeutic agents which results in enhancing 
the cytotoxic effect of doxorubicin, thus decreasing 
the dose of doxorubicin to reduce the side effect and 
avoid the cancer cell resistance to doxorubicin. 
 Curcumin, a phenolic compound of 
turmeric (Curcuma longa) is known to have 
cytotoxic properties by targeting various proteins 
involved in cell survival, metastasis, and 
angiogenesis. A study reported that curcumin 
also increases Reactive Oxygen Species (ROS) 
level through interaction with ROS metabolism 
enzymes such as glutathione S-transferase and 
Nicotinamide Adenine Dinucleotide Phosphate 
Hydrogen (NAD(P)H) dehydrogenase (Larasati, et 
al., 2018). The increase of ROS intracellular over 
cellular capacity tolerance of ROS could trigger 
senescence, a kind of cell cycle arrest that limits the 
replicative capacity of cells and induce apoptosis 
resulting in inhibition of the progression of cancer 
(Campisi, 2013). As co-chemotherapeutic agents, 
the combination of curcumin with doxorubicin 
enhances the cytotoxicity of doxorubicin in cancer 
through inhibition  of  efflux transporters which 
responsible for doxorubicin resistance (Tan and 
Norhaizan, 2019; Wen, et al., 2019). However, 
curcumin has low bioavailability that reduces the 
cytotoxic effect on in vivo study. Therefore, the 
development of curcumin analogs was carried out 
to find more potent compounds than curcumin. 
 Pentagamavunon-0 (PGV-0), one of the 
curcumin analogs was synthesized using vanillin 
and cyclopentanone. PGV-0 exhibits cytotoxic 
properties against several types of breast cancer 
such as T47D, Michigan Cancer Foundation-7 
(MCF-7), and MCF-7/Dox (Da’i, et al., 2012; 
Meiyanto, et al., 2014). The previous study reported 
that a combination of PGV-0 and doxorubicin 
showed an increase of cytotoxic and sensitivity 
effect of doxorubicin on MCF-7/Dox due to HER2 
with PgP inhibition and activation  in  the  nuclear 
factor  kappa-light-chain-enhancer of activated B 
cells (NF-κB) pathway (Meiyanto, et al., 2014). 
This present study aims to reveal the potential co-
chemotherapeutic effect of PGV-0 on 4T1 cells, 
as a model of TNBC. Furthermore, this study 
also investigates its effect on apoptosis, cellular 
senescence, and ROS level. The result of this study 
can be used as a foundation of a further experiment 
for the development of PGV-0 for TNBC.
MATERIAL AND METHOD
Chemical Material
 PGV-0 compound was obtained from 
Cancer Chemoprevention Research Center 
(CCRC), faculty of Pharmacy, Universitas Gadjah 
Mada. Doxorubicin was obtained from Wako Pure 
Chemical Industries, Ltd (Osaka, Japan).
Cell Culture 
 Cell line vero and cell line 4T1 (ATCCR-
CRL-2539TM) were obtained from Prof. Masashi 
Kawaichi, MD., Ph.D (Nara Institute of Science and 
Technology, NAIST, Nara, Japan). Cell cultured on 
high glucose Dulbecco’s Modified Eagles Medium 
(DMEM) (Gibco, New York, USA) supplemented 
with 10% Fetal Bovine Serum (FBS) (Sigma-
Aldrich, Missouri, USA) and 1.5% penicillin-
streptomycin (Gibco) (v⁄v) (Gibco) and then 
incubated at 37oC with 5% CO2. Cells were harvested 
from tissue culture disk (Iwaki, Tokyo, Japan) using 
0.25% trypsin-Ethylenediaminetetraacetic acid 
(EDTA) (Gibco).
Cytotoxic Assay 
 Cytotoxic assay was performed by 
3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazolium 
bromide (MTT) cell viability assay (Mosmann, 
1983). The 4T1 cell line (2.65x103 cell/well) and 
Vero cell (1x104 cell/well) were cultured at 96-
well plate. The cells were treated with various 
concentrations of PGV-0 and incubated in CO2 
incubator for 24 h at 37οC. After 24 h, culture media 
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were removed and cells washed using Phosphate-
buffered saline (PBS) IX. A total of 100 μL/well 
3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazolium 
bromide (MTT) solution (0.5 mg/mL) (Biovision, 
California, USA) were added. If formazan has been 
formed, a 10% Sodium Dodecyl Sulphate (SDS) 
solution (100 μL/well) was added then incubated 
overnight under room temperature. Absorbance 
measured  using a microplate reader (BioRad, 
California, USA) at 595 nm. The value of IC50 was 
calculated using linearity regression of cell viability, 
while its value was used to analyze the selectivity 
index (SI) of PGV-0. The value of SI>2 indicated 
that PGV-0 selective on 4T1 (Koch, et al., 2005).
Combination Cytotoxic Assay 
 Cytotoxic combination assay was 
performed using modified of MTT cell viability 
assay that described on previous study of PGV-
0 (Meiyanto, et al., 2014). The  4T1 cell line 
(2.65x103 cell/well) were cultured at 96-well plate 
and treated with combination of  PGV-0 (12.5 μM, 
25 μM, and 50 μM) and doxorubicin (10 nM and 
100 nM) in culture medium (100 μL/well). After 24 
h incubation on CO2 incubator at 37οC, cells were 
washed using PBS IX and 100 μL MTT solution 
(0.5 mg/mL) (Biovision) was added each well. A 
total of 100 μL/well SDS solution (10%) added to 
stop the formazan forming reaction. The cells were 
incubated  overnight  under  room  temperature. 
Absorbance measured using a microplate reader 
(BioRad) at 595 nm. The calculation of combination 
index (CI) was carried out to analyze combination 
effect of doxorubicin and PGV-0. The value of 
CI used to determine combination effect of both 
compound, whether synergistic (CI<0.9), additive 
(CI:0.9-1) or antagonistic (CI >1.1) (Huang, et al., 
2017).
Annexin V/PI Staining (Apoptosis Assay)
 A total of 4T1 1.5x106 cells/well were 
cultured at 6-well plate. The cells were treated 
with PGV-0 at a concentration of 50 μM and 
combination with doxorubicin (10 nM and 100 
nM). Treated cells were incubated for 24 h at 
37οC and 5% CO2. Cells were harvested using 
0.25% EDTA and collected at microtube. The 
cells were fixed using cold ethanol (70%) for 30 
minutes. After that, ethanol was removed from cells 
suspense, then added a solution of annexin V/PI 
(Roche, Hague Rd, Indianapolis, USA) 50μg/mL in 
binding buffer. Cells suspension was incubated in a 
CO2 incubator for 10 minutes at 37οC.  Apoptosis 
assay was performed using BD Accury C-6 
Flowcytometer at 488 nm. Data were presented 
as a percentage of early apoptosis, late apoptosis, 
and necrosis (Lakshmanan and Batra, 2013). 
Senescence-Associated β-Galactosidase (SA-
β-GAL) Assay
 The 4T1 (1.5x106 cell/well) were cultured 
at a 6-well plate. After 24 h incubation, medium 
culture  was  removed  and  the  cells   washed 
using 1X PBS. The cells were treated using PGV-
0 singly (25μM and 50μM) and combination with 
doxorubicin at concentration 10 nM. Cells were 
incubated at CO2 incubator for 24 h, 37οC. After 
that, the cells were fixed with paraformaldehyde 
(PFA) 4% for 10 minutes at room temperature, and 
then washed twice using 1X PBS. Each well given 
1 mL of Senescence-Associated β-Galactosidase 
(SA-β-GAL) dye solutions and incubated in 
incubator  non-CO2   at   37οC.  The  cells  were 
observed at 24, 48 and 72 h using an inverted 
microscope. The senescence cell was distinguished 
with blue-greenish color. Data were presented as the 
percentage of senescence cell (Eccles and Li, 2012). 
Analysis of Intracellular Reactive Oxygen 
Species (ROS) Using 2’,7’-dichlorofluorescein 
diacetate (DCFDA) Staining
 The 4T1 cell line (5x104 cell/well) were 
cultured in culture media (DMEM) at 24-well 
plate. The cells harvested using 300 μL trypsin-
EDTA. Trypsin was inactivated  using  500 μL 
supplemented buffer and collected at microtube. A 
total of 25 μM DCFDA solutions were given each 
well. Cells were incubated in a CO2 incubator, for 30 
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minutes at 37οC. After that, cells were treated with 
PGV-0 at concentration 50 μM and its combination 
with doxorubicin 10 nM. After 30 minutes of 
incubation, ROS analysis was performed using 
BD Accury C-6 Flowcytometer at 458 nm/535 nm. 
Mean fluorescence intensity was used to determine 
the ROS level on cells (Eruslanov and Kusmartsev, 
2010).
RESULTS 
Cytotoxic Effect of PGV-0 
 Several studies of PGV-0 revealed 
cytotoxic properties of PGV-0 on various types of 
breast cancer (Hermawan, et al., 2011; Meiyanto, 
et al., 2014). Nevertheless, the cytotoxic effect of 
PGV-0 on TNBC is not yet known. Therefore, we 
examine cytotoxic properties of PGV-0 on TNBC 
using a 4T1 cell line as a TNBC model and a Vero 
cell line as a normal cell. This research showed that 
PGV-0 has a cytotoxic effect on dose-dependent 
manner with IC50 values of 4T1 cells and vero 
cells were each 52 μM and 152 μM (Figure 1). The 
analysis of selectivity indicated that the cytotoxic 
effect of PGV-0 was selective on 4T1 cells (SI>2).
Cytotoxic Combination of PGV-0 with 
Doxorubicin 
 Based on the cytotoxic data above, PGV-0 
showed great potential as an anticancer compound. 
We assumed that the inhibitory effect of PGV-
0 was possibly enhancing the cytotoxic effect of 
doxorubicin on 4T1 cells. In this experiment, we 
investigate the cytotoxic effect of PGV-0 on 4T1 
in combination with doxorubicin. We used PGV-0 
at 12.5 μM, 25 μM, and 50 μM  combined  with 
doxorubicin at the concentration of 10 nM and 100 
nM. The results of combination treatment (Figure 
2) were reduced cell viability of 4T1 cells higher 
than single treatment of doxorubicin or PGV-0. 
The combination index value of each concentration 
less than 0.9 indicated a synergistic effect on 
4T1 cells (Table 1). This data suggested that the 
cytotoxic effect of combination treatment is greater 
than the sum of each effect on a single treatment. 
Apoptosis Induction Effect of Combination 
Doxorubicin and PGV-0 
 The combination of  PGV-0 and doxorubicin 
resulted in improved cytotoxicity of doxorubicin 
on 4T1 cells. To confirm the cellular mechanism 
of these combinatorial treatments, we performed 
apoptosis analysis using annexin V/PI assay. The 
results show that PGV-0 at concentration 50 μM 
induces apoptosis on 4T1 cells, while combination 
treatment increase apoptosis effect was better than 
single treatment of PGV-0 or doxorubicin (Figure 
3 and Table 2). However, looking at the data of 
Figure 1. Cytotoxicity of PGV-0 on 4T1 and Vero cells. The 4T1 cells (2.6x103 cell/well) and Vero (1x104 cell/
well) were cultured at 96 well-plate, then treated with various concentration of PGV-0. After 24 h incu-
bation, MTT solutions were added. SDS were given to stop formazan forming reaction, then incubated 
overnight. The IC50 values was calculated from the triplicate experiments (A) cytotoxic effect of PGV-0 on 
4T1, (B) cytotoxic effect of PGV-0 on Vero cell line.
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Figure 2. Cytotoxicity of Combination and single treatment on 4T1 cells. The 4T1 Cells (2.65x103 cell/well) 
were treated with combination of PGV-0 and doxorubicin (Dox) as described in the material and methods. 
After incubated for 24 h, the cells viability were measured using MTT assay. 
PGV-0
( M) 10 100
12.5 0.34 0.27
25 0.46 0.42
50 0.84 0.63
DOX (nM)
Table 1. Combination index (CI) analysis of doxorubicin with PGV-0. CI was used to determine interaction be-
tween each compound in combination treatment. Synergistic effect determined with CI value <0.9.
cytotoxic assay, the data of single treatment PGV-0 
(50 μM) of this experiment has higher death cells. 
We suspect this biased data may be occurred due to 
results of a long exposure of trypsin which resulted 
in leakage of cell metabolites  (Bundscherer, et al., 
2013). Regardless of these results, these data still 
give information that a combination of PGV-0 and 
doxorubicin may affect the  apoptosis mechanism 
of doxorubicin on 4T1 cells.
Senescence Induction Effect of Combination 
PGV-0 and Doxorubicin 
 Besides   apoptosis,  another  cellular 
mechanism that could be induced by anticancer 
compounds was senescence. Doxorubicin were 
known induce cellular senescence on cells. 
Therefore, these combinatioral treatment possibly 
affect senescence on 4T1. We were used SA-β-
GAL assay to determine senescence cells. The 
senescence cells were identified by blue-greenish 
color to cellular senescence, while the untreated 
cells is given no change of color. Observation using 
an inverted microscope detected cellular senescence 
within single and combination treatment (Figure 4). 
Single treatment of PGV-0 at concentration 25 μM 
and 50 μM showed that PGV-0 induce senescence 
each 2.03% and 3.13 % on 4T1 cells. Meanwhile, 
combination treatment were exhibit senescence 
cells each 6.99 % and 7.70% higher  than  single 
treatment  of  doxorubicin 10 nM (3.33%). These 
data suggested that administration of PGV-0 could 
enhance senescence effect of doxorubicin on 4T1.
ROS Level of Single Treatment PGV-0 and Its 
Combination 
 The increase of apoptosis and senescence 
corresponding to an increase of cellular stress. The 
cancer cells has higher level of ROS compared with 
normal cells. However, an increase of ROS level 
could lead to oxydative stress which lead to  both 
apoptosis and senescence. The combination of PGV-
0 and doxorubicin may be increased ROS level on 
4T1. Therefore  to  confirm  these  assumption, we 
also investigate ROS level on 4T1 cells. We were 
performed DCFDA staining assay to quantify ROS 
level on the 4T1 cells. The ROS level was calculated 
from fluorescence intensity given by the presence 
of DCF-fluorescence accumulated on cells. The 
single treatment of PGV-0 or doxorubicin increase 
ROS level, while combination of both compounds 
increases ROS level higher on 4T1 cells (Figure 5). 
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Dox 10 nM - + - - + - 
Dox 100 nM - - + - - + 
PGV-0 (50 M) - - - + + + 
Figure 3. Apoptosis effect of PGV-0, doxorubicin and combination of both compound on 4T1 cells. Cells were 
treated with single treatment and combination of PGV-0 and doxorubicin. Treated cells were harvested and 
collected at microtube, then stained using annexin V/PI. The cells were analysed using flowcytometry (A). 
Quantification cell death in each group (B). Quadrant analysis of cells on flowcytometry.
Untreated 
    Group Early apoptosis (%) Late apoptosis (%) Necrosis (%) 
Untreated 0.0 0.0 4.0 
Dox 10 nM 0.0 1.3 5.5 
Dox 100 nM 0.0 1.4 11.3 
PGV-0  0.0  80.8 14.4 
PGV-0 + dox 10  0.0  82.8 11.8 
PGV-0 + dox 100 0.0 88.0  10.2 
 
Table 2. Quantification of apoptosis and necrosis using annexin V/PI staining.
Untreated Dox 10 nM Dox 100 nM
PGV-0 50 µM  PGV-0 50 µM + dox 10 PGV-0 50 µM + dox 100
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Dox (10 nM) -  + -  -  +  +  
PGV-0 (25 M) -  - +  -  +  -  
PGV-0 (50 M) -  - -  +   - + 
 
 
Figure 4. Senescence induction effect of PGV-0 singly and combination with doxorubicin. The 4T1 cell line (1.5x106 
Cell/well) treated with single treatment of PGV-0 and combination with 10 nM doxorubicin. SA-β -GAL dye was 
given after 24 h treatment. Cellular senescence observed at 24, 48 and 72 h. (A) percentage of cellular se-
nescence (n=3, *=p<0.05, **= p<0.01) (B). Morphology of cell after 72 h staining (scale bars =10 μm). Inverted 
microscope was used to observed cellular senescence (200X).
 
Dox 10 nM - + - + 
PGV-0 (50 M) - - + + 
 
 
Figure 5. ROS level of 4T1 single treatment and combination PGV-0. Cells 4T1 culture (5x104 cell/well) were 
trypsinized and collected at microtube, then inactivated using supplemented buffer. DCFDA reagent (25 μM) 
were added to suspension cell. After that, suspension cells were treated with PGV-0 singly and its combination. 
After 4 h incubation, intensity ROS fluorescence analysed using flowcytometry instrument (*= p<0.05 **=p<0.01).
 
 *  p<0.05 
**p<0.01 
 
 *  p<0.05 
**p<0.01 
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DISCUSSION
 Doxorubicin   has   strong  anticancer 
properties against breast cancer, thus making its 
usage more preferred for chemotherapy especially 
for TNBC (O’Reilly, et al., 2015). However, long 
term use of doxorubicin was restricted due to the 
adverse effect and risk of doxorubicin’s resistance. 
Therefore, the exploration of co-chemotherapeutic 
agents urgently needed to improve the cytotoxicity 
of doxorubicin against cancer. This study aimed 
to explore the co-chemotherapeutic properties of 
PGV-0 on 4T1 cells as an in vitro model for TNBC. 
 PGV-0 compound is one of the potential 
curcumin analogs to be developed to improve the 
cytotoxicity of doxorubicin. Previously, PGV-0 
reported form synergistic effect with doxorubicin 
which enhances the sensitivity of doxorubicin 
on MCF-7 resistance doxorubicin (MCF-7/Dox) 
(Meiyanto, et al., 2014). In this present study, we 
found that PGV-0 form synergistic effect which en-
hances the cytotoxicity of doxorubicin on 4T1 cells. 
Interestingly, investigation on cellular mechanism 
shows that PGV-0 also increases induction effects 
of doxorubicin on senescence, ROS and possibly 
apoptosis. Considering those data, it is likely that 
the inhibitory effect of PGV-0 may be correlated 
with the increase of oxidative stress through a higher 
level   of  ROS  on  4T1  cells.   Several   studies 
reported  that  an  increase  of  ROS  over  cellular 
threshold could trigger activation pathways of se-
nescence and apoptosis, which led to the inducing 
of apoptosis and senescence on cells (Davalli, et al., 
2016; Redza-Dutordoir and Averill-Bates, 2016). 
Taken those finding above, PGV-0 may enhance the 
cytotoxicity of doxorubicin through the increase of 
the ROS intracellular level. Nevertheless, the mo-
lecular mechanism of PGV-0 remains undiscovered 
yet. Further investigation is needed to prove this 
hypothesis as well as revealed the mechanism mo-
lecular of PGV-0.
CONCLUSION
 Analog curcumin PGV-0 potential to be de-
veloped as a co-chemotherapeutic agent with doxo-
rubicin against TNBC.  
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